Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients
NCT ID: NCT01560299
Last Updated: 2012-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2010-02-28
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Some physicians advice to discontinue methimazole 3 days before radioiodine therapy and others prefer longer off - methimazole period which bothers most patients. This study aimed to evaluate optimum time for methimazole discontinuation in graves disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study of Different I-131 Doses in Graves' Disease
NCT02114619
Iodine Supplementation in Graves' Hyperthyroidism
NCT06540469
Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease
NCT05643365
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
NCT01295333
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
NCT05461820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group one
This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
Methimazole
Methimazole was stopped 24-48 before radio-iodine therapy
group two
methimazole stopped 48-72 hour before radioiodine therapy
Methimazole
methimazole discontinued 49-72 hours before radioiodine treatment
group three
Methimazole
methimazole discontinued 73-168 hours before radio-iodine treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methimazole
Methimazole was stopped 24-48 before radio-iodine therapy
Methimazole
methimazole discontinued 49-72 hours before radioiodine treatment
Methimazole
methimazole discontinued 73-168 hours before radio-iodine treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* graves disease(TSH\<0.1 \&increased FT4 \& positive TSI
* one or more bartlena criteria for radio-iodine therapy
* 24 hour RAIU\>25%
* euthyroidism after methimazole treatment
Exclusion Criteria
* moderate or severe graves ophthalmopathy
* CHF or coronary heart disease
* palpable thyroid nodule
* lithium or amiodarone or lugol or ipodate treatment
* recent imaging with contrast agent
* very large goiter(more than 150 gram)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mashhad University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
S.R.ZAKAVI
associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
rasoul zakavi, associate professor
Role: PRINCIPAL_INVESTIGATOR
Mashhad University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mashad University of Medical Sciences
Mashhad, Khorasan Razavi, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Metiodine
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.